Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
4.2.2 Increasing Healthcare Expenditure
4.2.3 Innovations in Drug Development
4.3 Market Restraints
4.3.1 Rise in the number of Patent Expirations
4.3.2 Asymptomatic Nature of the Disease
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Other Rare Types
5.2 By Therapeutics and Diagnostics
5.2.1 By Therapeutics
5.2.1.1 Chemotherapy
5.2.1.2 Immunotherapy
5.2.1.3 Radiation Therapy
5.2.1.4 Surgery
5.2.2 By Diagnostics
5.2.2.1 Cytoscopy
5.2.2.2 Biopsy
5.2.2.3 Urinalysis
5.2.2.4 Urine Ctyology
5.2.2.5 Bladder Ultrasound
5.3 Geography
5.3.1 Latin America (LATAM)
5.3.1.1 Mexico
5.3.1.2 Brazil
5.3.1.3 Argentina
5.3.1.4 Rest of Latin America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca Plc.
6.1.2 Bristol Myers Squibb
6.1.3 Celgene Corporation
6.1.4 Eli Lilly and Co.
6.1.5 GlaxoSmithKline Plc.
6.1.6 Merck & Co., Inc.
6.1.7 Johnson and Johnson
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi S.A.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS